Document:

Exhibit 10.10

 

Pursuant to Item 601(b)(10)(iv) of Regulation S-K, certain identified information marked with [*****] has been excluded from the exhibit
because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.

 

Second Amendment to Exclusive License
Agreement between The UAB Research

Foundation (“UABRF”) and Incysus, Ltd. 

 

This Second Amendment
to Exclusive License Agreement (this “Second Amendment”) is made effective as of January 26, 2017 (the “Second
Amendment Effective Date”) by and between The UAB Research Foundation (“UABRF”) and Incysus, Ltd. (“Licensee”).
Licensee and UABRF may be each individually referred to as a party and collectively, the parties (“Party” or “Parties”).

 

RECITALS

 

WHEREAS, UABRF and
Licensee previously entered into that certain Exclusive License Agreement dated effective as of March 10, 2016 (“Agreement”);

 

WHEREAS, the Parties
have previously amended the Agreement by executing that certain First Amendment, as of December 14, 2016, in which UABRF licensed
to the Licensee it’s right, title and interest in certain jointly owned intellectual property jointly owned by the Parties
and which was conceived subsequent to the Effective Date of the Agreement (the “First Amendment”);

 

WHEREAS, subsequent
to the Effective Date of the Agreement, further intellectual property has been conceived by [*****] and other employees of the
University of Alabama at Birmingham which is solely owned by UABRF and which the Parties are interested in including in the Licensed
Patents;

 

WHEREAS, such additional
intellectual property described in UABRF intellectual property disclosure number [*****] entitled “[*****]” was developed
by [*****] while employed by the University of Alabama at Birmingham (the “Inventors”);

 

WHEREAS, UABRF has
filed for patent protection with respect to such additional intellectual property and has filed US Provisional Patent Application
No. [*****] entitled “[*****]” filed [*****] (the “Additional Patent”);

 

WHEREAS, the Parties
wish to amend the Agreement to extend the scope of the Agreement to include the additional intellectual property; and

 

NOW, THEREFORE, for
good and valuable consideration, the Parties agree to amend the Agreement as follows:

 

AGREEMENT

 

1.       All
capitalized terms used herein shall bear the meaning ascribed to them in the Agreement unless otherwise defined herein.

 

2.       Inclusion
of Additional Licensed Patent. As of the Second Amendment Effective Date, the Additional Patent shall comprise part of
the Licensed Patents as described in Section 1.13 of the Agreement and Exhibit A of the Agreement is hereby amended to read
as follows (with new language being shown in italics and underlined:

 

    1

     

    

 

Exhibit A. Licensed
Patents (dated as of the Effective Date)

 

		(a)	[*****]

		(b)	[*****]

		(c)	[*****]

 

3.       Updating
of Exhibit B. As of the Second Amendment Effective Date, Exhibit B of the Agreement is deleted in its entirety and replaced
with the document marked as Exhibit B attached to this Second Amendment

 

4.       All
other terms and conditions of the Agreement shall remain in full force and effect.

 

{Signatures on following
page}

 

    2

     

    

 

IN WITNESS WHEREOF, UABRF
and Licensee have each caused its duly authorized representative to execute this Second Amendment, effective as of the date written
above.

 

	UABRF:	 	Company:
	The
    UAB Research Foundation	 	Incysus,
    Ltd.,
	 
	By:
    	/s/
    Authorized Signatory	 	By:	/s/
    Tom Cirrito
	 	 	Name: Tom
    Cirrito
	 	 	Title: Board
    Member
	 	 	 

	Date Signed:	    1/26/17	 	Date Signed:	   April 25, 2017

  

    3

     

    

 

 

EXHIBIT B

 

[*****] 

 

    4Exhibit 10.11

 

Pursuant to Item
601(b)(10)(iv) of Regulation S-K, certain identified information marked with [*****] has been excluded from the exhibit because
it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.

 

Third Amendment
to Exclusive License Agreement between The UAB Research 

Foundation (“UABRF”) and Incvsus, Ltd. 

 

This Third Amendment
to Exclusive License Agreement (this “Third Amendment”) is made effective as of the date of the last signature of the
Parties (as evidenced below their signatures on the signature page) (the “Third Amendment Effective Date”) by and between
The UAB Research Foundation (“UABRF”) and Incysus, Ltd. (“Licensee”). Licensee and UABRF may be each individually
referred to as a party and collectively, the parties (“Party” or “Parties”).

 

RECITALS

 

WHEREAS, UABRF and
Licensee previously entered into that certain Exclusive License Agreement dated effective as of March 10, 2016 (“Original
Agreement”);

 

WHEREAS, the Parties
have previously amended the Original Agreement by executing that certain First Amendment, as of December 14, 2016, in which UABRF
licensed to the Licensee it’s right, title and interest in certain jointly owned intellectual property jointly owned by the
Parties and which was conceived subsequent to the Effective Date of the Agreement (the “First Amendment”) (together,
the “Original Agreement” and the “First Amendment” constitute the “Agreement”);

 

WHEREAS, the Parties
are, contemporaneous with the execution of this Third Amendment, also amending the Agreement by executing that certain Second Amendment
pursuant to which the Licensee is licensing additional intellectual property and an additional patent application is being included
in Licensed Patents; and

 

WHEREAS, the Parties
wish to further amend the Agreement to clarify when payments under section 5.7 of the Agreement are due.

 

NOW, THEREFORE, for
good and valuable consideration, the Parties agree to amend the Agreement as follows:

 

AGREEMENT

 

1.       All
capitalized terms used herein shall bear the meaning ascribed to them in the Agreement unless otherwise defined herein.

 

2.       Section
5.7. Section 5.7 is deleted in its entirety and replaced with the following language:

 

“With
respect to the first calendar year in which the cumulative Net Sales accomplished by the Licensee, its Affiliates and
sublicensees reaches or exceeds the threshold amount set forth in the first column of the table below, the Licensee shall pay
to UABRF the corresponding lump sum amount set forth in the second column. The three lump sum payments due to UABRF under
this section shall be paid within [*****] of the close of the calendar year in which the obligation to pay is triggered. The
lump sum payments due under this section 5.7 are in addition to the royalty amounts due pursuant to section 5.5 of this
Agreement.

 

    1

     

    

 

	Cumulative Net Sales	Lump Sum Amount Due
	[*****]	[*****]
	[*****]	[*****]
	[*****]	[*****]

 

3.       All
other terms and conditions of the Agreement shall remain in full force and effect.

 

IN WITNESS WHEREOF, UABRF
and Licensee have each caused its duly authorized representative to execute this Third Amendment, effective as of the date written
above.

 

	UABRF:

    The UAB Research Foundation	 	Licensee:

    Incysus, Ltd.
	 	 	 
	By:	/s/
    Authorized Signatory	 	By:	 /s/
    Tom Cirrito
	 	 	Name: Tom Cirrito
	Date Signed: June 16, 2017	 	Title: Board Member
	 	 	Date Signed:  April 25, 2017

 

    2Exhibit 10.12

 

Pursuant to Item 601(b)(10)(iv) of
Regulation S-K, certain identified information marked with [*****] has been excluded from the exhibit because it is both (i) not
material and (ii) would be competitively harmful if publicly disclosed.

 

Fourth Amendment to Exclusive License
Agreement between The UAB Research

Foundation (“UABRF”) and Incysus Therapeutics, Inc. 

 

This Fourth Amendment
to Exclusive License Agreement (this “Fourth Amendment”) is made effective as of the date of the last signature of
the Parties (as evidenced below their signatures on the signature page) (the “Fourth Amendment Effective Date”) by
and between The UAB Research Foundation (“UABRF”) and Incysus Therapeutics, Inc. (previously known as Incysus, Ltd.)
(“Licensee”). Licensee and UABRF may be each individually referred to as a party and collectively, the parties (“Party”
or “Parties”).

 

RECITALS

 

WHEREAS, UABRF and
Licensee previously entered into that certain Exclusive License Agreement dated effective as of March 10, 2016 (“Original
Agreement”);

 

WHEREAS, the Parties
have previously amended the Original Agreement by executing those certain First, Second and Third Amendments, effective as of December
16, 2016, January 26, 2017 and June 16, 2017, respectively (together, the Original Agreement and all amendments, the “Agreement”);

 

WHEREAS, since the
Third Amendment Effective Date, additional intellectual property has been conceived by [*****] and employees of the Licensee and
thus is jointly owned by the Licensee and UABRF;

 

WHEREAS, such additional
intellectual property is described in UABRF intellectual property disclosure number [*****] entitled “[*****]”;

 

WHEREAS, the Licensee
has filed for patent protection with respect to such additional intellectual property and has filed US Provisional Patent Application
No. [*****], entitled “[*****]” and filed on [*****] (the “Additional Jointly Owned Patent”);

 

WHEREAS, the Licensee
wishes to obtain exclusive rights to such additional intellectual property and the Additional Jointly Owned Patent and UABRF is
willing to grant to the Licensee the right to exclusively use of all of UABRF’s right, title and interest in and to such
additional intellectual property and to exclusively practice all of UABRF’s rights in and to the Additional Jointly Owned
Patent;

 

WHEREAS, the Parties
wish to amend the Agreement to include the additional intellectual property and the Additional Jointly Owned Patent;

 

WHEREAS, as of May
7, 2018, the Licensee discontinued business as Incysus, Ltd. in the country of Bermuda and reincorporated in the United States
of America under the laws of the State of Delaware as Incysus Therapeutics, Inc.; and

 

    1

     

    

 

WHERAS, the Parties
wish to update the Agreement with the new corporate details of the Licensee.

 

NOW, THEREFORE. for
good and valuable consideration, the Parties agree to amend the Agreement as follows:

 

AGREEMENT

 

1.       All
capitalized terms used herein shall bear the meaning ascribed to them in the Agreement unless otherwise defined herein.

 

2.       Inclusion
of Additional Jointly Owned Patent. As of the Fourth Amendment Effective Date, the Additional Jointly Owned Patent shall comprise
part of the Licensed Patents as described in Section 1.13 of the Agreement and Exhibit A of the Agreement is hereby amended to
read as follows (with new language being shown in italics and underlined:

 

Exhibit A. Licensed
Patents (dated as of the Effective Date)

 

		(a)	[*****]

		(b)	[*****]

		(c)	[*****]

		(d)	[*****]

 

3.       Update
Certain Corporate Information regarding the Licensee. The Parties acknowledge that the Licensee has changed corporate structure
and jurisdiction of incorporation and that it discontinued business as Incysus, Ltd. in the country of Bermuda and reincorporated
in the United States of America under the laws of the State of Delaware as Incysus Therapeutics, Inc. All references to Incysus,
Ltd. shall be deleted and replaced with Incysus Therapeutics, Inc. In addition, the address for notices relating to the licensee
and appearing below the signature of the Licensee shall be deleted in its entirety and replaced with the following language:

 

Incysus Therapeutics,
Inc.

79 Madison Avenue

New York, NY 10016.

 

4.       All
other terms and conditions of the Agreement shall remain in full force and effect.

 

[Signatures on following
page]

 

    2

     

    

 

 

IN WITNESS WHEREOF, UABRF
and Licensee have each caused its duly authorized representative to execute this Fourth Amendment.

 

	UABRF:	 	Company:
	The
    UAB Research Foundation	 	Incysus,
    Ltd.,
	 
	By:	/s/
    Authorized Signatory	 	By:	/s/
    William Ho
	 	 	Name: William
    Ho
	 	 	Title: CEO
	 

 

	Date Signed:	   11/26/17
     	 	Date Signed:	    November
    15, 2018

 

    3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00315-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00315-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00315-of-00352.parquet"}]]